To develop the next generation of in vivo T cell therapy, Novartis will leverage Vyriad's active targeting lentiviral vector platform to discover and develop new in vivo CAR-T cell therapy candidates.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback